This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Vistide

Starting date:
February 11, 2013
Posting date:
March 1, 2013
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-23811

Recalled Products

A. Vistide

Reason

During secondary packaging run on January 29, 2013, of another sub-lot (B120217K), vials with floating particulate matter were noted.

Depth of distribution

Shipped to 12 Canadian hospitals:

  • Alberta Children's Hospital (Calgary)
  • Children’s and Women’s HC of BC (Vancouver)
  • Canadian Forces Medical Center (Petawawa ON)
  • Winnipeg HC Center
  • Hull Hospital (Gatineau)
  • Chaleur Regional Hospital (Bathurst NB)
  • Hotel Dieu of Quebec City
  • Peter Lougheed Center (Calgary)
  • Princess Margaret Hospital (Toronto)
  • Royal Alexandra Hospital (Edmonton)
  • Royal University Hospital (Saskatoon)
  • Vancouver General Hospital

Affected products

A. Vistide

DIN, NPN, DIN-HIM
Nil
Dosage form

Intravenous infusion

Strength

75 mg / mL

Lot or serial number

B1207217A

Companies
Recalling Firm
Gilead Sciences
333 Lakeside Drive
Foster City
94404
California
UNITED STATES
Marketing Authorization Holder
N/A

Date modified: